ABUSArbutus Biopharma Corporation
What is the market doing?
Rangebound. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Rangebound, no clear trend. Oversold (RSI 23). Price is −8% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ABUS is trading
Arbutus Biopharma Corporation is −2.7% over the past year while the S&P 500 is +18%: 21 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −7.9%
vs 200-day average · below trend, but not far
- RSI (14)
- 23
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 20%
Below its 52-week high
Details›
- Last close2026-10-08
- $4.18
- 1 monthS&P 500 +1.6%
- −19%
- 1 yearS&P 500 +18%
- −2.7%
- 5 yearsS&P 500 +86%
- −2.7%
- vs 50-day average$4.83
- −14%
- 52-week high
- $5.20
- 52-week low
- $3.67
- Annualised volatility
- 45%
| Year | Return |
|---|---|
| 2026 (year to date) | −13% |
| 2025 | +47% |
| 2024 | +31% |
| 2023 | +7.3% |
| 2022 | −40% |
| 2021 | +9.6% |
| 2020 | +28% |
| 2019 | −27% |
| 2018 | −24% |
| 2017 | +106% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | −1.0% |
| Feb | 10 | 8 of 10 | +7.9% |
| Mar | 10 | 3 of 10 | −9.0% |
| Apr | 10 | 6 of 10 | −2.5% |
| May | 10 | 5 of 10 | +6.9% |
| Jun | 10 | 6 of 10 | +2.9% |
| Jul | 11 | 5 of 11 | +13% |
| Aug | 11 | 5 of 11 | −0.03% |
| Sep | 11 | 6 of 11 | +8.0% |
| Oct | 11 | 2 of 11 | −8.3% |
| Nov | 10 | 5 of 10 | +4.0% |
| Dec | 10 | 4 of 10 | +6.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.